Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panther: Copanlisib + Trastuzumab in Pretreated HER2+ Breast Cancer
NCT02705859Phase 1Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Apr 2016
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in breast cancer, sponsored by Cancer Trials Ireland. Primary endpoints: Maximum Tolerated Dose at 1 year and Clinical Benefit Rate at 1 year. Started Apr 2016; status: completed.
02
Drugs
copanlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02705859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705859.